The Impact of Probiotics and Prebiotics on Dry Eye Disease Signs and Symptoms.

clinical research dry eye disease eye symptoms prebiotic probiotic treatment

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
20 Aug 2022
Historique:
received: 21 06 2022
revised: 04 08 2022
accepted: 15 08 2022
entrez: 26 8 2022
pubmed: 27 8 2022
medline: 27 8 2022
Statut: epublish

Résumé

Dry eye is considered an inflammatory disease. Gut microbiota are important in the regulation of low-grade chronic inflammation, including in the eye. Probiotics and prebiotics are increasingly used to regulate chronic-disease-associated gut dysbiosis. Therefore, this double-masked, randomized controlled clinical trial aimed to explore the potential of oral probiotics and prebiotics in the management of dry eye disease. In total, 41 participants with dry eye received probiotic and prebiotic supplements (treatment group, n = 23) or respective placebos (control group, n = 18) for 4 months. Dry eye symptoms and signs were evaluated using the Ocular Surface Disease Index (OSDI), Dry Eye Questionnaire 5, osmolarity, non-invasive keratograph break-up time (NIKBUT), ocular surface staining, tear meniscus height (TMH), lipid layer thickness, and conjunctival redness. After 4 months, the average OSDI score of the treatment group was significantly better compared to that of the controls (16.8 ± 5.9 vs. 23.4 ± 7.4; p < 0.001). The NIKBUT and TMH did not change significantly with treatment (p = 0.31 and p = 0.84) but reduced significantly for controls on average by −5.5 ± 1.0 secs (p = 0.03) and 0.2 ± 0.1 mm (p = 0.02). These data suggest that probiotics and prebiotics might be effective in the management of dry eye disease.

Identifiants

pubmed: 36013128
pii: jcm11164889
doi: 10.3390/jcm11164889
pmc: PMC9409742
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Brien Holden Vision Institute
ID : The study was conducted as part of a postgraduate education grant supported by the Brien Holden Vision Institute.

Références

Trials. 2017 Jan 9;18(1):7
pubmed: 28069054
Clin Exp Immunol. 2016 May;184(2):248-56
pubmed: 26690299
Ocul Surf. 2017 Jul;15(3):539-574
pubmed: 28736342
Cont Lens Anterior Eye. 2022 Apr;45(2):101408
pubmed: 33485805
J Biosci. 2019 Oct;44(5):
pubmed: 31719219
Ocul Surf. 2017 Jul;15(3):438-510
pubmed: 28736340
Eye Contact Lens. 2021 Oct 1;47(10):555-558
pubmed: 34393179
Med Arch. 2021 Apr;75(2):144-148
pubmed: 34219875
Curr Opin Ophthalmol. 2018 May;29(3):261-266
pubmed: 29538183
Arthritis Res Ther. 2017 Oct 24;19(1):237
pubmed: 29065905
Postgrad Med J. 2002 Jun;78(920):366-7
pubmed: 12151695
Dtsch Arztebl Int. 2015 Jan 30;112(5):71-81; quiz 82
pubmed: 25686388
Ophthalmol Ther. 2020 Sep;9(3):499-513
pubmed: 32617914
Sci Rep. 2016 Apr 18;6:23561
pubmed: 27087247
Ocul Surf. 2017 Jul;15(3):334-365
pubmed: 28736337
Ocul Surf. 2016 Apr;14(2):255-63
pubmed: 26795265
Ocul Surf. 2017 Jul;15(3):366-403
pubmed: 28736338
Sci Rep. 2022 Apr 13;12(1):6214
pubmed: 35418586
Curr Eye Res. 2016;41(2):171-8
pubmed: 25803436
Int Rev Immunol. 2013 Feb;32(1):19-41
pubmed: 23360156
J Autoimmun. 2019 Feb;97:77-87
pubmed: 30416033
Clin Ter. 2017 May-Jun;168(3):e181-e185
pubmed: 28612893
Int J Mol Sci. 2020 Nov 10;21(22):
pubmed: 33182758
North Clin Istanb. 2018 Aug 08;5(4):319-322
pubmed: 30859162
Invest Ophthalmol Vis Sci. 2020 Mar 9;61(3):42
pubmed: 32232342
Invest Ophthalmol Vis Sci. 2002 Feb;43(2):340-7
pubmed: 11818375
Am J Ophthalmol. 2015 Dec;160(6):1150-1153.e3
pubmed: 26302236
Invest Ophthalmol Vis Sci. 2000 Mar;41(3):687-91
pubmed: 10711682
Invest Ophthalmol Vis Sci. 2013 Jul 18;54(7):4821-6
pubmed: 23766472
PLoS One. 2020 Feb 14;15(2):e0229029
pubmed: 32059038
Ophthalmic Physiol Opt. 2022 Jan;42(1):140-148
pubmed: 34665479
Microb Cell Fact. 2020 Apr 15;19(1):90
pubmed: 32293464
Ocul Surf. 2017 Jul;15(3):276-283
pubmed: 28736335
Front Microbiol. 2018 Jul 20;9:1618
pubmed: 30072976
Ophthalmic Physiol Opt. 2021 Nov;41(6):1254-1266
pubmed: 34545606
Neuroscience. 2015 Oct 29;307:171-90
pubmed: 26272535
Front Immunol. 2018 May 24;9:1106
pubmed: 29881381

Auteurs

Azadeh Tavakoli (A)

Brien Holden Vision Institute, Sydney 2052, Australia.
School of Optometry, Vision Science University of New South Wales, Sydney 2052, Australia.

Maria Markoulli (M)

School of Optometry, Vision Science University of New South Wales, Sydney 2052, Australia.

Eric Papas (E)

School of Optometry, Vision Science University of New South Wales, Sydney 2052, Australia.

Judith Flanagan (J)

School of Optometry, Vision Science University of New South Wales, Sydney 2052, Australia.
Vision CRC, Sydney 2052, Australia.

Classifications MeSH